MX2024013985A - Metodos de tratamiento de la glomeruloesclerosis focal y segmentaria con atrasentan - Google Patents
Metodos de tratamiento de la glomeruloesclerosis focal y segmentaria con atrasentanInfo
- Publication number
- MX2024013985A MX2024013985A MX2024013985A MX2024013985A MX2024013985A MX 2024013985 A MX2024013985 A MX 2024013985A MX 2024013985 A MX2024013985 A MX 2024013985A MX 2024013985 A MX2024013985 A MX 2024013985A MX 2024013985 A MX2024013985 A MX 2024013985A
- Authority
- MX
- Mexico
- Prior art keywords
- atrasentan
- methods
- segmental glomerulosclerosis
- subject
- focal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263343574P | 2022-05-19 | 2022-05-19 | |
| PCT/US2023/022681 WO2023225163A1 (en) | 2022-05-19 | 2023-05-18 | Methods of treating focal segmental glomerulosclerosis with atrasentan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024013985A true MX2024013985A (es) | 2025-02-10 |
Family
ID=88836135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024013985A MX2024013985A (es) | 2022-05-19 | 2024-11-12 | Metodos de tratamiento de la glomeruloesclerosis focal y segmentaria con atrasentan |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250352511A1 (enExample) |
| EP (1) | EP4525857A4 (enExample) |
| JP (1) | JP2025517355A (enExample) |
| KR (1) | KR20250013180A (enExample) |
| CN (1) | CN119325377A (enExample) |
| AU (1) | AU2023271840A1 (enExample) |
| CA (1) | CA3252232A1 (enExample) |
| IL (1) | IL316349A (enExample) |
| MX (1) | MX2024013985A (enExample) |
| WO (1) | WO2023225163A1 (enExample) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9255931B2 (en) * | 2010-06-24 | 2016-02-09 | Morehouse School Of Medicine | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
| US20170014386A1 (en) * | 2015-07-16 | 2017-01-19 | Abbvie, Inc. | Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children |
| CA3010593C (en) * | 2016-01-05 | 2024-02-13 | University Of Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
| IL294410B2 (en) * | 2016-11-23 | 2024-02-01 | Chemocentryx Inc | A method for the treatment of focal segmental tuberous sclerosis |
| HRP20260121T1 (hr) * | 2019-12-17 | 2026-03-13 | Chinook Therapeutics, Inc. | Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije |
-
2023
- 2023-05-18 JP JP2024568249A patent/JP2025517355A/ja active Pending
- 2023-05-18 IL IL316349A patent/IL316349A/en unknown
- 2023-05-18 KR KR1020247041241A patent/KR20250013180A/ko active Pending
- 2023-05-18 AU AU2023271840A patent/AU2023271840A1/en active Pending
- 2023-05-18 CN CN202380039968.2A patent/CN119325377A/zh active Pending
- 2023-05-18 CA CA3252232A patent/CA3252232A1/en active Pending
- 2023-05-18 WO PCT/US2023/022681 patent/WO2023225163A1/en not_active Ceased
- 2023-05-18 EP EP23808292.9A patent/EP4525857A4/en active Pending
- 2023-05-18 US US18/867,358 patent/US20250352511A1/en active Pending
-
2024
- 2024-11-12 MX MX2024013985A patent/MX2024013985A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025517355A (ja) | 2025-06-05 |
| EP4525857A1 (en) | 2025-03-26 |
| AU2023271840A1 (en) | 2024-10-31 |
| EP4525857A4 (en) | 2026-05-20 |
| KR20250013180A (ko) | 2025-01-31 |
| IL316349A (en) | 2024-12-01 |
| US20250352511A1 (en) | 2025-11-20 |
| CA3252232A1 (en) | 2023-11-23 |
| CN119325377A (zh) | 2025-01-17 |
| WO2023225163A1 (en) | 2023-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022551456A1 (en) | Methods of treating iga nephropathy with atrasentan | |
| MX2022012557A (es) | Metodos de tratamiento de la enfermedad renal diabetica. | |
| MX2022000143A (es) | Metodos novedosos. | |
| MX2022012992A (es) | Inhibidores de kif18a para el tratamiento de enfermedades neoplasicas. | |
| EA202092343A1 (ru) | Лечение гнойного гидраденита с использованием ингибиторов jak | |
| AR119158A1 (es) | Tratamientos de angioedema hereditario | |
| PE20230180A1 (es) | Uso de bi853520 en tratamiento contra el cancer | |
| WO2018102687A3 (en) | Combination therapy for treating cancer | |
| MX2025013118A (es) | Tratamiento combinado para una enfermedad o un trastorno relacionado con ras | |
| EP4684836A3 (en) | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases | |
| MX2020008359A (es) | Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción. | |
| CL2020003171A1 (es) | Dosis y efecto de un antagonista de c5a con una vasculitis asociada a anca. | |
| JP2022546985A5 (enExample) | ||
| ECSP22066085A (es) | ANTICUERPOS CONTRA LA INTEGRINA alfaVß8 PARA SU USO EN EL TRATAMIENTO DE LA ENFERMEDAD RENAL | |
| CO2023017973A2 (es) | Trampas de ligando del factor de crecimiento transformante βeta para el tratamiento de enfermedades | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| CL2022000790A1 (es) | Método para tratar vih con cabotegravir y rilpivirina | |
| MX2021003606A (es) | Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv. | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| AR122933A1 (es) | Métodos para tratar la enfermedad cardiovascular | |
| MX2021014523A (es) | Metodos para tratar colangiocarcinoma. | |
| MX2021002590A (es) | Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor. | |
| ZA202201070B (en) | Focal treatment of prostate cancer | |
| MX2025000142A (es) | Tratamiento con ciclobenzaprina para las secuelas postagudas de la infección por (sars)-cov-2 (pasc) | |
| WO2023019095A3 (en) | Momelotinib combination therapy |